VALERIO THERAPEUTICS

🇫🇷France

Country: 🇫🇷France

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

Phase 2

Completed

Conditions: Carcinoma of Unknown Primary

Interventions: Drug: belinostat, carboplatin, paclitaxel
Drug: carboplatin, paclitaxel

First Posted Date: 2009-04-01

Last Posted Date: 2015-07-28

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 89

Registration Number: NCT00873119

Locations: 🇺🇸
Oncology Hematology Care Inc., Cincinnati, Ohio, United States
🇺🇸
Tennessee Oncology Sarah Cannon Research, Nashville, Tennessee, United States
🇺🇸
South Texas Oncology and Hematology, San Antonio, Texas, United States

and more 20 locations

Phase 3 Clinical Study for the Treatment of Cold Sore

Phase 3

Completed

Conditions: Herpes Labialis

Interventions: Drug: Acyclovir Lauriad
Drug: Placebo

First Posted Date: 2008-10-09

Last Posted Date: 2012-12-21

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 1727

Registration Number: NCT00769314

Locations: 🇵🇱
Naukowo-Badawczy i Naukowo-Dydaktyczny Ośrodek Dermatologii Estetycznej, Dermatochirurgii i Fotodermatologii, Gdynia, Poland
🇵🇱
Gabinet Internistyczny, Warszawa, Poland
🇵🇱
NZOZ Atopia, Al. J., Kraków, Poland

and more 46 locations

Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines

Phase 2

Completed

Conditions: Anthracycline Extravasation

First Posted Date: 2007-10-24

Last Posted Date: 2015-10-21

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 23

Registration Number: NCT00548561

Locations: 🇩🇰
Aalborg Hospital South, Aalborg, Denmark
🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇰
Herlev County Hospital, Herlev, Denmark

and more 6 locations

A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines

Phase 2

Completed

Conditions: Extravasation

First Posted Date: 2007-10-24

Last Posted Date: 2015-10-21

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 57

Registration Number: NCT00548704

Locations: 🇵🇱
Centre of Oncology - Krakow Division, Krakow, Poland
🇵🇱
Dolnoslaski Centrum Onkologii oddzial Chemoterapii, Wroclaw, Poland
🇩🇰
Aarhus County Hospital, Aarhus, Denmark

and more 30 locations

A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: APO010

First Posted Date: 2007-02-21

Last Posted Date: 2015-09-17

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 26

Registration Number: NCT00437736

Locations: 🇨🇭
Oncology Institute of Southern Switzerland, Hospital of Bellinzona, Bellinzona, Switzerland
🇨🇭
Multidisciplinary Oncology Center, Cantonal University Hospital of Vaud, Lausanne, Switzerland

A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL

Phase 1

Completed

Conditions: B-cell Chronic Lymphocytic Leukemia

Interventions: Drug: APO866

First Posted Date: 2007-02-14

Last Posted Date: 2015-09-23

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 10

Registration Number: NCT00435084

Locations: 🇬🇧
Department of Heamtology, Cardiff and Vale NHS Trust, Cardiff, United Kingdom
🇬🇧
Department of Heamtology, Leeds General Infirmary, Leeds, United Kingdom
🇬🇧
Department of Heamtology, Bart's and the London NHS Trust, London, United Kingdom

and more 1 locations

A Study to Assess APO866 for the Treatment of Advanced Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: APO866

First Posted Date: 2007-02-07

Last Posted Date: 2015-09-29

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 25

Registration Number: NCT00432107

Locations: 🇦🇹
Department of Dermatology, Medical University Graz, Graz, Austria
🇫🇷
Department of Dermatologie, Hotel Dieu, Nantes, France
🇫🇷
Department of Dermatology, Hopital Henri Modor, Créteil, France

and more 3 locations

A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma

Phase 2

Completed

Conditions: Cutaneous T-cell Lymphoma

Interventions: Drug: APO866

First Posted Date: 2007-02-06

Last Posted Date: 2015-07-08

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 25

Registration Number: NCT00431912

Locations: 🇨🇭
Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland
🇦🇹
Department of Dermatology, Medical University Graz, Graz, Austria
🇫🇷
department of Dermatologie, Hotel Dieu, Nantes, France

and more 2 locations

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

Phase 2

Terminated

Conditions: Multiple Myeloma

First Posted Date: 2007-02-05

Last Posted Date: 2015-07-08

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 4

Registration Number: NCT00431340

Locations: 🇺🇸
Oncotherapeutics, West Hollywood, California, United States
🇺🇸
Center for cancer and blood disorders, Bethesda, Maryland, United States
🇺🇸
Baylor University Medical Center, Dallas, Texas, United States

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Phase 1

Completed

Conditions: Ovarian Cancer
Epithelial Ovarian Cancer
Bladder Cancer
Fallopian Tube Cancer

Interventions: Drug: belinostat
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2007-01-15

Last Posted Date: 2015-07-28

Lead Sponsor: Valerio Therapeutics

Target Recruit Count: 80

Registration Number: NCT00421889

Locations: 🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States
🇺🇸
Hematology & Oncology Specialists, LLC, Metairie, Louisiana, United States
🇬🇧
The Royal Marsden NHS Trust, Surrey, United Kingdom

and more 8 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy